Cantor Fitzgerald Lowers Disc Medicine Price Target After FDA Issues Complete Response Letter
Cantor Fitzgerald trimmed its price target on Disc Medicine (IRON) to $125 from $153 while retaining an Overweight rating after the U.S. Food and Drug Administration issued a complete response letter for bitopertin. The agency requested additional trial evidence linking the surrogate endpoint to a clinical endpoint; the ongoing Phase 3 APOLLO study…